ALAR PHARMACEUTICALS INC.
Area: Government, Academia and Research Institutes
Booth No: N604
Website: https://alarpharm.com/
Exhibitor Profile
Alar Pharmaceuticals Inc. focuses on developing innovative long-acting injectables (LAI) drug products for CNS disorders through the 505(b)(2) regulatory pathway. These formulations are designed to release the active ingredient steadily over a period ranging from several weeks to several months following single subcutaneous injection. Current product pipeline includes LAIs for opioid use disorder, alcohol use disorder, treatment-resistant depression, Parkinson’s disease, and schizophrenia.
Brands
ALAR PHARMACEUTICALS INC.
Video
Exhibit Products
-
ALA-4000, a sustained release apomorphine injectable for Parkinson's disease
-
ALA-1000, a sustained released buprenorphine injectable for opioid use disorder or chronic pain
-
ALA-3000, a sustained release ketamine injectable for treatment-resistant depression
-
ALA-5000, a sustained release injectable for Schizophrenia
-
ALA-2000, a sustained release naltrexone injectable for alcohol use disorder or opioid use disorder
Exhibitors you may be interested in
Highest Rated